|D058186||Acute Kidney Injury NIH||0.15|
|D002318||Cardiovascular Diseases NIH||0.12|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
There are 2 clinical trials
The trial was designed to assess the effect of daily dose of 300 mg omega-3 supplements for 2 months on the selected interleukins levels in uninfected people with Covid-19.
Description: pg/mLMeasure: IL-1 beta Time: (2 months ; 60 days )
Description: pg/mlMeasure: IL-6 Time: (2 months ; 60 days )
Description: pg/mlMeasure: TNF alpha Time: (2 months ; 60 days )
Description: mg/dLMeasure: Lipid profile Time: (2 months ; 60 days )
Description: mg/dlMeasure: Fasting blood glucose Time: (2 months ; 60 days )
The Renin-Angiotensin-Aldosterone System (RAAS) is involved in blood pressure regulation and electrolyte balance. Angiotensin-converting enzyme (ACE) is a critical regulator of RAAS by cleaving angiotensin (Ang1) to Angiotensin2 (Ang2), which is the most powerful biologically active product of RAAS . In the same context, angiotensin-converting enzyme 2 (ACE2) converts Ang2 to Ang (1-7), which is a vasodilator, antithrombotic, and antihypertrophic peptide . ACE2 which is found in many tissues  has opposite effects to ACE on the heart, kidneys, and lungs . Many pathological conditions, in particular cardiovascular disease (CVD), have shown a link between a disturbance in ACE/ACE2 ratio and the downregulation of ACE2 levels . Also, ACE/ACE2 has been reported to be higher in moderate to severe chronic heart failure  as well as systolic blood pressure . Recently, an elevated ACE/ACE2 ratio is linked to Coronavirus disease 2019 (COVID-19). SARS-COV2 enters target cells by binding of the spike protein to ACE2 and a specific transmembrane serine protease 2 (TMPRSS2) for the spike (S) protein priming, which also leads to downregulation of ACE2 . Down-regulation of ACE2 caused by Coronavirus may have a potential role in the pathogenesis of COVID-19 infection. Accordingly, people with a higher ACE/ACE2 ratio may be more at increased risk of worse Covid-19 consequences . On the other hand, omega-3 fatty acids could decrease CVD risk by their anti-inflammatory anti-thrombotic function . A meta-analysis comprising 15,806 patients, showed that omega-3 fatty acids associated with a 30% reduction in fatal myocardial infarction and sudden death, in addition to a 20% reduction in overall mortality . To the best of our knowledge, no clinical trials have evaluated the effect of omega-3 supplementation on serum ACE/ACE2 ratio which is recently ascribed as a potential key in 2019 Covid-19 as well as CVD [5,9].
Description: Angiotensin converting enzyme levels pg/mLMeasure: serum ACE levels Time: 10 weeks
Description: Angiotensin converting enzyme-2 levelsMeasure: serum ACE2 levels Time: 10 weeks
Description: TC,LDL,HDL,TGMeasure: Lipid profile mg/dL Time: 10 weeks
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports